A Phase 1 interventional study of PF-02341066 and PF-02341066 in Healthy, sponsored by Pfizer. Completed at 1 site in Japan. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-29.
Sponsored by Pfizer · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate the pharmacokinetics of single doses of PF-02341066 (150, 250, and 400 mg) in the fasted condition in Japanese healthy male volunteers.
The purpose of this study is to investigate the pharmacokinetics of single doses of PF-02341066 (150, 250, and 400 mg) in the fasted condition in Japanese healthy male volunteers.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study will consist of three cohorts: PF-02341066 150 mg treatment group (n = 6), PF-02341066 250 mg treatment group (n = 6) and PF-02341066 400 mg treatment group (n = 6).
Drug: PF-02341066
Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib
AUC(0-inf) of crizotinib is estimated from the crizotinib concentration. It is obtained from AUClast plus (Clast/kel). AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration. Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Crizotinib
AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Maximum Plasma Concentration (Cmax) of Crizotinib
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Time to Cmax (Tmax) of Crizotinib
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Terminal Elimination Half-life (t1/2) of Crizotinib
t1/2 of crizotinib is the time measured for the plasma concentration to decrease by one half. It is obtained from a Loge(2)/kel. Kel = terminal phase elimination rate constant
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Apparent Oral Clearance (CL/F) of Crizotinib
CL/F of crizotinib is obtained from a Dose per AUCinf.
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Apparent Volume of Distribution (Vz/F) of Crizotinib
Vz/F of crizotinib is obtained from a Dose / (AUCinf \*kel). Kel = terminal phase elimination rate constant
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Dose Normalized AUC(0-inf) of Crizotinib
Dose normalized (to 150 mg dose) AUC(0-inf) is obtained from AUC(0-inf) / (Dose/150).
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Dose Normalized AUClast of Crizotinib
Dose normalized (to 150 mg dose) AUClast is obtained from AUClast / (Dose/150).
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Dose Normalized Cmax of Crizotinib
Dose normalized (to 150 mg dose) Cmax is obtained from Cmax / (Dose/150).
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUC0-inf) of Plasma Active Metabolite (PF-06260182)
AUC(0-inf) of PF-06260182 is estimated from the PF-06260182 concentration. It is obtained from AUClast plus (Clast/kel). AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration. Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Plasma Active Metabolite (PF-06260182)
AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Maximum Plasma Concentration (Cmax) of Plasma Active Metabolite (PF-06260182)
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Time to Cmax (Tmax) of Plasma Active Metabolite (PF-06260182)
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Metabolite to Parent Ratio AUC(0-inf)
The metabolic ratio (MR) is calculated by first converting the AUC(0-inf) for both crizotinib and metabolite (PF-06260182) from mass units to molar units.
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Metabolite to Parent Ratio AUClast
The metabolic ratio (MR) is calculated by first converting the AUClast for both crizotinib and metabolite (PF-06260182) from mass units to molar units.
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
Metabolite to Parent Ratio Cmax
The metabolic ratio (MR) is calculated by first converting the Cmax for both crizotinib and metabolite (PF-06260182) from mass units to molar units.
Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 144 hours post-dose
| Milestone | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Started | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 |
AUC(0-inf) of crizotinib is estimated from the crizotinib concentration. It is obtained from AUClast plus (Clast/kel). AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration. Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.
| ng*hr/mL | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib | 1423 ± 471.52 | 3806 ± 1313.2 | 6569 ± 2098.3 |
AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.
| ng*hr/mL | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Crizotinib | 1339 ± 472.66 | 3732 ± 1312.4 | 6386 ± 2084.7 |
| ng/mL | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Crizotinib | 70.54 ± 25.570 | 155.6 ± 50.694 | 235.8 ± 60.988 |
| ng/mL | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Time to Cmax (Tmax) of Crizotinib | 5.00 (5.00 to 6.00) | 5.00 (4.00 to 6.00) | 5.00 (5.00 to 6.00) |
t1/2 of crizotinib is the time measured for the plasma concentration to decrease by one half. It is obtained from a Loge(2)/kel. Kel = terminal phase elimination rate constant
| hours | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Terminal Elimination Half-life (t1/2) of Crizotinib | 41.08 ± 6.7683 | 29.90 ± 3.9945 | 29.13 ± 3.5753 |
CL/F of crizotinib is obtained from a Dose per AUCinf.
| liter per hour | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Apparent Oral Clearance (CL/F) of Crizotinib | 105.4 ± 33.926 | 65.70 ± 30.500 | 60.87 ± 16.936 |
Vz/F of crizotinib is obtained from a Dose / (AUCinf \*kel). Kel = terminal phase elimination rate constant
| Liter | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Crizotinib | 6170 ± 2843.7 | 2811 ± 1765.0 | 2545 ± 958.43 |
Dose normalized (to 150 mg dose) AUC(0-inf) is obtained from AUC(0-inf) / (Dose/150).
| ng*hr/mL | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Dose Normalized AUC(0-inf) of Crizotinib | 1423 ± 471.52 | 2284 ± 787.92 | 2463 ± 786.84 |
Dose normalized (to 150 mg dose) AUClast is obtained from AUClast / (Dose/150).
| ng*hr/mL | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Dose Normalized AUClast of Crizotinib | 1339 ± 472.66 | 2239 ± 787.45 | 2395 ± 781.75 |
Dose normalized (to 150 mg dose) Cmax is obtained from Cmax / (Dose/150).
| ng/mL | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Dose Normalized Cmax of Crizotinib | 70.54 ± 25.570 | 93.36 ± 30.416 | 88.41 ± 22.870 |
AUC(0-inf) of PF-06260182 is estimated from the PF-06260182 concentration. It is obtained from AUClast plus (Clast/kel). AUClast = area under the plasma concentration-time curve from zero time until the last measurable concentration. Clast = the last quantifiable concentration. Kel = terminal phase elimination rate constant.
| ng*hr/mL | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUC0-inf) of Plasma Active Metabolite (PF-06260182) | 180.8 ± 99.369 | 535.8 ± 274.23 | 1046 ± 549.90 |
AUClast of crizotinib is estimated from the crizotinib concentration. It is obtained from Linear/Log trapezoidal method.
| ng*hr/mL | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Plasma Active Metabolite (PF-06260182) | 188.1 ± 81.706 | 527.2 ± 273.68 | 1034 ± 547.34 |
| ng/mL | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Plasma Active Metabolite (PF-06260182) | 17.24 ± 6.2371 | 37.63 ± 18.372 | 54.94 ± 14.633 |
| ng/mL | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Time to Cmax (Tmax) of Plasma Active Metabolite (PF-06260182) | 5.00 (4.00 to 6.00) | 5.00 (4.00 to 6.00) | 6.00 (5.00 to 8.00) |
The metabolic ratio (MR) is calculated by first converting the AUC(0-inf) for both crizotinib and metabolite (PF-06260182) from mass units to molar units.
| ratio | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Metabolite to Parent Ratio AUC(0-inf) | 0.1261 ± 0.0200 | 0.1365 ± 0.0272 | 0.1544 ± 0.0343 |
The metabolic ratio (MR) is calculated by first converting the AUClast for both crizotinib and metabolite (PF-06260182) from mass units to molar units.
| ratio | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Metabolite to Parent Ratio AUClast | 0.1362 ± 0.0262 | 0.1370 ± 0.0272 | 0.1571 ± 0.0347 |
The metabolic ratio (MR) is calculated by first converting the Cmax for both crizotinib and metabolite (PF-06260182) from mass units to molar units.
| ratio | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| Metabolite to Parent Ratio Cmax | 0.2371 ± 0.0833 | 0.2346 ± 0.0441 | 0.2260 ± 0.0429 |
Collected over For serious adverse event, up to 28 days after the last administration of the study drugs. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Crizotinib 150 mg | — | 0/6 (0%) | 2/6 (33.3%) |
| Crizotinib 250 mg | — | 0/6 (0%) | 0/6 (0%) |
| Crizotinib 400 mg | — | 0/6 (0%) | 1/6 (16.7%) |
| Event | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/6 | 0/6 | 0/6 |
| Alanine aminotransferase increasedInvestigations | 1/6 | 0/6 | 0/6 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 1/6 |
| Age, Categorical(Participants) | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 6 | 18 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Crizotinib 150 mg | Crizotinib 250 mg | Crizotinib 400 mg | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 6 | 18 |
The record gives a start of Dec 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crizotinib